AUTHENTICATED
U.S. GOVERNMENT
INFORMATION
GPO

119th Congress, 2d Session – – – – – – – – – – – – House Document 119–150

# ADJUSTING IMPORTS OF PHARMACEUTICALS AND PHARMACEUTICAL INGREDIENTS INTO THE UNITED STATES

---

## MESSAGE

FROM

# THE PRESIDENT OF THE UNITED STATES

TRANSMITTING

A NOTIFICATION OF ACTION TO ADJUST IMPORTS OF PHARMACEUTICALS AND PHARMACEUTICAL INGREDIENTS SO THAT SUCH IMPORTS WILL NOT THREATEN TO IMPAIR THE NATIONAL SECURITY OF THE UNITED STATES, PURSUANT TO 19 U.S.C. 1862(c)(2); PUBLIC LAW 87–794, SEC. 232 (AS AMENDED BY PUBLIC LAW 100–418, SEC. 1501(a)(3)); (102 STAT. 1258)



APRIL 21, 2026.—Message and accompanying papers referred to the Committee on Ways and Means and ordered to be printed

---

U.S. GOVERNMENT PUBLISHING OFFICE
69–011 WASHINGTON : 2026

*To the Congress of the United States:*

Consistent with applicable law, including section 232(c)(2) of the Trade Expansion Act of 1962, as amended (19 U.S.C. 1862(c)(2)) (section 232), I am submitting to the Congress this written statement of the reasons why I have decided to take action to adjust imports of pharmaceuticals and pharmaceutical ingredients so that such imports will not threaten to impair the national security of the United States.

On January 5, 2026, the Secretary of Commerce (Secretary), in accordance with section 232, transmitted to me a report on his investigation into the effects of imports of pharmaceuticals and pharmaceutical ingredients on the national security of the United States. Based on the facts considered in that investigation, the Secretary found and advised me of his opinion that pharmaceuticals and associated active pharmaceutical ingredients, including key starting materials, are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States.

In Proclamation 11020 of April 2, 2026 (Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into The United States) (Proclamation), after considering the Secretary's report, the factors in section 232(d) (19 U.S.C. 1862(d)), and other relevant factors and information, among other things, I concurred with the Secretary's finding that pharmaceuticals and associated pharmaceutical ingredients are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States. In my judgment, and in light of the Secretary's report, the factors in section 232(d) (19 U.S.C. 1862(d)), and other relevant factors and information, I determined that it is necessary and appropriate to adopt a plan of action to adjust such imports of pharmaceuticals and associated pharmaceutical ingredients so that such imports will not threaten to impair the national security of the United States. In particular, I determined that it is necessary and appropriate for the Secretary and the Secretary of Health and Human Services, and any senior official they deem appropriate, to pursue or continue pursuing negotiations of agreements to address the threatened impairment of the national security with respect to imported pharmaceuticals and pharmaceutical ingredients. In the Proclamation, I noted that depending on the status or outcome of those negotiations, I may take other measures to adjust the imports of pharmaceuticals and pharmaceutical ingredients to address the threat to the national security found in the Proclamation. I also determined that it is necessary and appropriate to impose an immediate *ad valorem* duty rate on the import of certain patented pharmaceuticals and associated pharmaceutical ingredients to address the national security threat found in the Proclamation.

I am enclosing a copy of the Proclamation that I have issued. The Proclamation further explains the circumstances underlying the threat to impair the national security of the United States posed by imports of pharmaceuticals and pharmaceutical ingredients and the actions taken in the Proclamation to eliminate that threat.

DONALD J. TRUMP.

THE WHITE HOUSE, *April 16, 2026*.

# ADJUSTING IMPORTS OF PHARMACEUTICALS AND PHARMACEUTICAL INGREDIENTS INTO THE UNITED STATES

---

## BY THE PRESIDENT OF THE UNITED STATES OF AMERICA

## A PROCLAMATION

1. The Secretary of Commerce (Secretary) recently transmitted to me a report on his investigation into the effects of imports of pharmaceuticals and pharmaceutical ingredients on the national security of the United States under section 232 of the Trade Expansion Act of 1962, as amended, 19 U.S.C. 1862 (section 232). Based on the facts considered in that investigation, and taking into account the close relation of the economic welfare of the Nation to our national security and other relevant factors, *see* 19 U.S.C. 1862(d), the Secretary found and advised me of his opinion that pharmaceuticals and associated active pharmaceutical ingredients (APIs), including key starting materials, are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States.

2. The Secretary found that the present quantities and circumstances of imports of pharmaceuticals and pharmaceutical ingredients threaten to impair the national security and economy. Despite being the world leader in research and development (R&D) for most innovative pharmaceuticals (those that are typically patented and branded, as compared to generic pharmaceuticals or pharmaceuticals approved pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355(j)), the United States is heavily reliant on imports, threatening to limit United States access to life-saving medications in the event of global supply chain disruption due to geopolitical or economic disruption. According to the Food and Drug Administration, as of 2025, approximately 53 percent of patented pharmaceutical products distributed domestically are produced outside the country. The degree of import reliance is significant at the API level with only 15 percent of patented APIs by volume domestically produced for the United States market.

3. The Secretary found that patented pharmaceuticals and associated pharmaceutical ingredients are essential to the United States' military and civilian healthcare. A self sufficient domestic manufacturing and industrial base for pharmaceutical products is vital for the ability to support national defense requirements and maintain public health security during a national emergency or wartime. Patented pharmaceuticals are pivotal for treating cancer, rare diseases, autoimmune disorders, infectious diseases, and other critical health challenges. The Secretary further found that foreign government intervention has undermined the competitiveness of

the United States patented pharmaceutical industry. This intervention has led to further dependence on foreign production of patented pharmaceuticals that have fragile supply chains.

4. In light of these findings, the Secretary recommended actions to adjust imports of patented pharmaceuticals and associated pharmaceutical ingredients, including continuing to negotiate onshoring agreements related to Most-Favored-Nation (MFN) pharmaceutical pricing agreements; imposing significant tariffs on pharmaceuticals and pharmaceutical ingredients, so that such imports will not threaten to impair the national security of the United States; and granting preferential treatment to those companies that commit to onshore production of pharmaceuticals and pharmaceutical ingredients.

5. After considering the Secretary's report, the factors in section 232(d) (19 U.S.C. 1862(d)), and other relevant factors and information, among other things, I concur with the Secretary's finding that pharmaceuticals and associated pharmaceutical ingredients are being imported into the United States in such quantities and under such circumstances as to threaten to impair the national security of the United States. In my judgment, and in light of the Secretary's report, the factors in section 232(d) (19 U.S.C. 1862(d)), and other relevant factors and information, I have also determined that it is necessary and appropriate to adopt a plan of action, as described below, to adjust such imports of pharmaceuticals and associated pharmaceutical ingredients so that such imports will not threaten to impair the national security of the United States.

6. I have decided to direct the Secretary and the Secretary of Health and Human Services to pursue negotiations of agreements or continue any current negotiations of agreements, such as agreements contemplated in section 232(c)(3)(A)(i) (19 U.S.C. 1862(c)(3)(A)(i)), to address the threatened impairment of the national security with respect to imported patented pharmaceuticals and associated pharmaceutical ingredients, with any party the Secretary and the Secretary of Health and Human Services deem appropriate, and to update me on the progress of such negotiations within 90 days of the date of this proclamation. Under current circumstances and in light of future requirements of the United States, this action is necessary and appropriate to address the threatened impairment of the national security.

7. I have determined that it is necessary and appropriate to impose a 100 percent *ad valorem* duty rate on the import of patented pharmaceuticals and associated pharmaceutical ingredients, as identified in Annex I to this proclamation, and except as otherwise provided in this proclamation. Pharmaceutical products and ingredients that are subject to the section 232 zero tariff at this time are listed in Annex IV to this proclamation.

8. I have determined that it is necessary and appropriate that the *ad valorem* duty rate be 20 percent on imports of patented pharmaceuticals and associated pharmaceutical ingredients produced by companies that have plans, approved by the Secretary, to onshore production of such pharmaceuticals and pharmaceutical ingredients. The aforementioned 20 percent rate shall increase to 100 percent 4 years after the date of this proclamation.

9. I have further determined that it is necessary to implement pharmaceutical-related commitments in existing trade deals with the European Union, Japan, the Republic of Korea, and Switzerland and Liechtenstein jointly, as well as a future pharmaceutical-related deal with the United Kingdom (on which the United States and the United Kingdom have reached an agreement in principle as of December 1, 2025). These deals further United States economic and national security interests.

10. I further find that it is necessary and appropriate to impose no tariffs on imports of patented pharmaceuticals and associated pharmaceutical ingredients produced by companies that have fully executed agreements or are negotiating agreements with the Secretary and the Secretary of Health and Human Services regarding MFN pricing and onshoring of production and R&D of patented pharmaceuticals and pharmaceutical ingredients. Such agreements further United States economic and national security interests by making pharmaceuticals more accessible and affordable in the United States and by strengthening the domestic manufacturing base.

11. I have further determined not to adjust imports of generic pharmaceuticals and their associated ingredients, including biosimilar products, at this time. This determination includes purchases of generic pharmaceuticals and ingredients for the Strategic API Reserve. I find that such products should not be subject to section 232 tariffs at this time.

12. In my judgment, based on current circumstances as well as the future needs of the United States, the actions in this proclamation are necessary and appropriate to address the threatened impairment of the national security posed by imports of pharmaceuticals and pharmaceutical ingredients.

13. Section 232 authorizes the President to take action to adjust the imports of an article and its derivatives that are being imported into the United States in such quantities or under such circumstances as to threaten to impair the national security. Section 232 includes the authority to adopt and carry out a plan of action, with adjustments over time, to address the national security threat. This plan of action may include negotiations of agreements along with other actions to adjust imports to address the national security threat, including tariffs. If action under section 232 includes the negotiation of an agreement, such as one contemplated in section 232(c)(3)(A)(i) (19 U.S.C. 1862(c)(3)(A)(i)), the President may also take other actions he deems necessary to adjust imports to eliminate the threat that the imported article poses to the national security, including if such an agreement is not entered into within 180 days of the date of this proclamation, is not being carried out, or is ineffective. *See* 19 U.S.C. 1862(c)(3)(A).

14. Section 604 of the Trade Act of 1974, as amended (19 U.S.C. 2483) (section 604), authorizes the President to embody in the Harmonized Tariff Schedule of the United States (HTSUS) the substance of statutes affecting import treatment, and actions thereunder, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction.

NOW, THEREFORE, I, DONALD J. TRUMP, President of the United States of America, by the authority vested in me by the

Constitution and the laws of the United States, including section 232, 19 U.S.C. 1862; section 604, 19 U.S.C. 2483; and section 301 of title 3, United States Code, do hereby proclaim as follows:

(1) The Secretary and the Secretary of Health and Human Services, and any senior official they deem appropriate, shall pursue or continue pursuing negotiations of agreements, as contemplated in section 232(c)(3)(A)(i) (19 U.S.C. 1862(c)(3)(A)(i)), to address the threatened impairment of the national security with respect to imported pharmaceuticals and pharmaceutical ingredients.

(2) I hereby ratify, and delegate to the Secretary the authority necessary to enter into, the company-specific tariff agreements listed in Annex II to this proclamation that the Secretary entered into prior to this proclamation. I also hereby delegate to the Secretary the authority to enter into and implement similar agreements in the future, as referenced in clause (1) of this proclamation. The Secretary is authorized to monitor and enforce these agreements as he deems appropriate, consistent with clause (6) of this proclamation and applicable law.

(3)(a) Imports of patented pharmaceuticals and associated pharmaceutical ingredients, as listed in Annex I to this proclamation, will be subject to a 100 percent *ad valorem* duty rate.

(b) The *ad valorem* duty rate for patented pharmaceuticals and associated pharmaceutical ingredients, as listed in Annex I to this proclamation, shall be 20 percent for products of companies that have, or that the Secretary assesses are likely soon to have (e.g., based on agreements in principle), onshoring plans approved by the Secretary. The aforementioned 20 percent rate shall increase to 100 percent on April 2, 2030.

(c) The *ad valorem* duty rate for patented pharmaceuticals and associated pharmaceutical ingredients, as listed in Annex I to this proclamation, shall be 15 percent for products of Japan, the European Union, the Republic of Korea, and Switzerland and Liechtenstein jointly, unless a lower rate applies under clause (3) of this proclamation. The tariff rate on patented pharmaceuticals and associated pharmaceutical ingredients for products of the United Kingdom shall be 10 percent and then reduce to zero to the extent required by any future agreement between the United States and the United Kingdom on pharmaceutical pricing. The Secretary shall publish a *Federal Register* notice should the rate for the United Kingdom be reduced to zero.

(d) The *ad valorem* tariff rate shall be zero for drugs and associated ingredients, where all approved indications are designated as orphan pursuant to the Orphan Drug Act, 21 U.S.C. 360aa *et seq*., and its implementing regulations; nuclear medicines; plasma derived therapies; fertility treatments; cell and gene therapies; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; or other specialty pharmaceutical products to be identified by the Secretary, as well as pharmaceutical products for animal health, provided that the Secretary, in consultation with the United States Trade Representative (Trade Representative) and the Secretary of Health and Human Services, determines that: (1) they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement as referenced in Executive Order 14346 of Sep-

tember 5, 2025 (Modifying the Scope of Reciprocal Tariffs and Establishing Procedures for Implementing Trade and Security Agreements), or (2) they meet an urgent United States health need. The Secretary shall publish a *Federal Register* notice whenever he makes such a determination.

(e) For companies that are eligible for the tariff treatment outlined in clause (3)(b) of this proclamation, and that have entered into MFN pharmaceutical pricing agreements with the Secretary of Health and Human Services, the applicable *ad valorem* tariff rate for pharmaceuticals and associated pharmaceutical ingredients shall be zero until January 20, 2029. The Secretary shall apply this zero tariff rate to companies that he determines are likely to be eligible soon (e.g., because they have agreements in principle with the Secretary and the Secretary of Health and Human Services). For avoidance of doubt, this zero tariff rate shall also apply per the terms of the agreements listed in Annex II to this proclamation.

(f) The Secretary may increase the tariff rates referenced in clause (2) of this proclamation, and in clauses (3)(b) and (3)(e) of this proclamation, to address companies' failure to fulfill commitments under the relevant plans and agreements. The Secretary, in consultation with the Trade Representative, may increase the tariff rates referenced in clause (3)(c) of this proclamation to address foreign jurisdictions' failure to fulfill commitments under agreements with the United States. The Secretary shall publish a *Federal Register* notice when tariff rates are increased.

(4) The tariffs and tariff treatment imposed by this proclamation shall be effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern daylight time on July 31, 2026, for the companies listed in Annex III to this proclamation and September 29, 2026, for other companies and shall continue in effect, unless such actions are expressly reduced, modified, or terminated.

(5) Generic pharmaceuticals and their associated ingredients shall not be subject to tariffs pursuant to section 232 at this time. Within 1 year of the date of this proclamation, the Secretary shall, in consultation with any senior executive branch officials the Secretary deems appropriate, inform the President of any circumstances that, in the Secretary's opinion, might indicate the need to take action to adjust the imports of generic pharmaceuticals and their associated ingredients.

(6) The Secretary, in consultation with the Secretary of Health and Human Services, shall establish criteria for onshoring plans referenced in clause (3)(b) of this proclamation, to be published in the *Federal Register*. All onshoring plans shall be subject to approval, monitoring, and enforcement by the Secretary. The Secretary shall require companies with qualifying onshoring plans to submit periodic reports to the Secretary regarding progress towards fulfilling onshoring milestones. The Secretary may require that such reports be audited by an external auditing firm. In cases where the executive branch assesses that a company engaged in fraud or deliberately misled the United States Government with respect to onshoring commitments, the Secretary may reimpose tariffs discussed in this proclamation both prospectively and retroactively on imports from relevant companies, and he may impose

other tariffs and penalties to the extent consistent with applicable law.

(7) If a product is subject to tariffs under this proclamation and Column 1 of the HTSUS (Column 1 Duty Rate), then the sum of the additional section 232 tariff imposed pursuant to this proclamation and the applicable Column 1 Duty Rate shall be equal to the applicable rate listed in clause (3) of this proclamation, unless the Column 1 Duty Rate is greater than the applicable rate listed in clause (3) of this proclamation, in which case only the Column 1 Duty Rate shall apply. This clause does not apply to the tariff treatment for products of the United Kingdom described in clause (3)(c) of this proclamation.

(8) If a product is subject to more than one rate of duty under this proclamation, then the lowest applicable rate shall apply.

(9) The Secretary, in consultation with the Chair of the United States International Trade Commission and the Commissioner of U.S. Customs and Border Protection (CBP), shall determine whether any modifications to the HTSUS or other administrative measures are necessary to effectuate or implement this proclamation or any actions taken pursuant to this proclamation. Any changes shall be published in a notice in the *Federal Register*.

(10) Drawback shall be available with respect to the duties imposed pursuant to this proclamation.

(11) Imports of United States-origin pharmaceutical products shall not be subject to the tariffs imposed by this proclamation at this time.

(12) To the extent permitted by applicable law, CBP may take any necessary or appropriate measure to administer the tariffs imposed or altered by this proclamation. Importers shall provide to CBP information necessary to carry out this proclamation.

(13) Any product described in clause (4) of this proclamation, except those eligible for admission as "domestic status" as described in 19 CFR 146.43, that is subject to a duty imposed by this proclamation and that is admitted into a United States foreign trade zone on or after the effective date of this proclamation, must be admitted as "privileged foreign status" as described in 19 CFR 146.41 and will be subject upon entry for consumption to any *ad valorem* rates of duty related to the classification under the applicable HTSUS subheading.

(14) The Secretary shall continue to monitor imports of patented and generic pharmaceuticals and pharmaceutical ingredients. The Secretary also shall, from time to time, in consultation with any senior executive branch officials the Secretary deems appropriate, review the status of such imports with respect to the national security. The Secretary shall inform me of any circumstances that, in the Secretary's opinion, might indicate the need for further action by the President under section 232. The Secretary shall also inform me of any circumstance that, in the Secretary's opinion, might indicate that the tariff imposed in this proclamation is no longer necessary.

(15) To the extent consistent with applicable law and the purpose of this proclamation, the Secretary, the Secretary of Health and Human Services, and the Secretary of Homeland Security are directed and authorized to take all actions that are appropriate to

implement and effectuate this proclamation and any actions contemplated by this proclamation, including, consistent with applicable law, the issuance of regulations, rules, guidance, and procedures and the temporary suspension or amendment of regulations, within their respective jurisdictions, and to employ all powers granted to me under section 232.

(16) The Secretary, the Trade Representative, and the Secretary of Homeland Security may, consistent with applicable law, including section 301 of title 3, United States Code, redelegate any of these functions within their respective executive departments or agencies.

(17) Any provision of previous proclamations and Executive Orders that is inconsistent with this proclamation is superseded to the extent of such inconsistency. If any provision of this proclamation or the application of any provision of this proclamation to any individual or circumstance is held to be invalid, the remainder of this proclamation and the application of its provisions to any other individual or circumstance shall not be affected.

IN WITNESS WHEREOF, I have hereunto set my hand this second day of April, in the year of our Lord two thousand twenty-six, and of the Independence of the United States of America the two hundred and fiftieth.

DONALD J. TRUMP.

**Annex I**

MODIFICATIONS TO
THE HARMONIZED TARIFF SCHEDULE OF THE UNITED STATES

A. Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on July 31, 2026, subchapter III of chapter 99 of the Harmonized Tariff Schedule of the United States ("HTSUS") is modified as follows:

1. The following new U.S. note 40 is inserted in numerical order:

"(a) Headings 9903.04.60–9903.04.69 provide the customs duty treatment of imported articles classifiable in one of the provisions of the HTSUS enumerated in subdivision (c) of this note.

These headings are mutually exclusive, such that an imported article will be subject to no more than one of these headings. Pharmaceutical articles, as defined in subdivisions (c)(i)–(iii) of this note, are subject to heading 9903.04.60 unless another of these headings applies.

(b) For imported articles subject to headings 9903.04.60–9903.04.68 that are eligible for special tariff treatment under any of the free trade agreements or preference programs listed in general note 3(c)(i) to the tariff schedule, the duties provided in these headings shall be collected in addition to any special rate of duty otherwise applicable under the appropriate tariff subheading. Goods for which entry is claimed under a provision of chapter 98 of the HTSUS and which are subject to the additional duties prescribed herein shall be eligible for and subject to the terms of such provision and applicable U.S. Customs and Border Protection ("CBP") regulations. No claim for entry or for any duty exemption or reduction shall be allowed under a provision of chapter 99 of the HTSUS that may set forth a lower rate of duty or provide duty-free treatment, taking into account information supplied by CBP.

All antidumping, countervailing, or other duties and charges applicable to such goods shall continue to be imposed.

(c) The headings provided in subdivision (a) of this note and the defined terms of this subdivision apply to articles that are classifiable in the following provisions of the HTSUS:

| | | |
|---|---|---|
| 2918.99.3000 | 2921.49.3800 | 2921.49.4300 |
| 2922.19.0900 | 2922.29.2700 | 2922.49.2600 |
| 2922.50.1400 | 2922.50.2500 | 2924.29.6250 |
| 2925.29.2000 | 2928.00.3000 | 2930.90.9235 |
| 2931.90.2200 | 2932.20.2000 | 2933.19.3500 |
| 2933.19.4500 | 2933.29.2000 | 2933.29.4500 |
| 2933.39.4100 | 2933.49.2600 | 2933.59.2100 |
| 2933.59.3600 | 2933.59.4600 | 2933.59.5300 |

| | | |
|---|---|---|
| 2933.59.5900 | 2933.79.0800 | 2933.79.8500 |
| 2933.99.4600 | 2933.99.5300 | 2933.99.5590 |
| 2933.99.6100 | 2933.99.6500 | 2933.99.7000 |
| 2933.99.7500 | 2933.99.9000 | 2934.30.2300 |
| 2934.30.2700 | 2934.99.3000 | 2934.99.4700 |
| 2935.90.4800 | 2935.90.6000 | 2937.11.0000 |
| 2937.12.0000 | 2937.19.0000 | 2937.22.0000 |
| 2937.23.1010 | 2937.23.1050 | 2937.23.5010 |
| 2937.23.5020 | 2937.23.5050 | 2937.29.9040 |
| 2937.29.9050 | 2937.29.9095 | 2937.50.0000 |
| 2937.90.4500 | 2937.90.9000 | 2938.90.0000 |
| 2939.11.0000 | 2939.19.2000 | 2939.19.5000 |
| 2941.10.5000 | 2941.90.1050 | 2941.90.3000 |
| 2941.90.5000 | 2942.00.0500 | 3002.12.0040 |
| 3002.13.0010 | 3002.13.0090 | 3002.14.0010 |
| 3002.14.0090 | 3002.15.0011 | 3002.15.0091 |
| 3002.41.0000 | 3002.42.0000 | 3002.49.0050 |
| 3002.51.0000 | 3002.59.0000 | 3002.90.1000 |
| 3002.90.5220 | 3002.90.5250 | 3003.20.0000 |
| 3003.31.0000 | 3003.39.1000 | 3003.39.5000 |
| 3003.49.0000 | 3003.90.0120 | 3003.90.0140 |
| 3003.90.0180 | 3003.90.0190 | 3004.10.1010 |
| 3004.10.5010 | 3004.20.0010 | 3004.20.0083 |
| 3004.31.0000 | 3004.32.0060 | 3004.39.0010 |
| 3004.39.0055 | 3004.41.0000 | 3004.49.0005 |
| 3004.49.0010 | 3004.49.0020 | 3004.49.0030 |
| 3004.49.0040 | 3004.49.0050 | 3004.49.0060 |
| 3004.49.0070 | 3004.50.5005 | 3004.90.1000 |
| 3004.90.9201 | 3004.90.9206 | 3004.90.9208 |
| 3004.90.9210 | 3004.90.9211 | 3004.90.9215 |
| 3004.90.9216 | 3004.90.9225 | 3004.90.9236 |
| 3004.90.9243 | 3004.90.9246 | 3004.90.9249 |
| 3004.90.9251 | 3004.90.9252 | 3004.90.9253 |
| 3004.90.9260 | 3004.90.9263 | 3004.90.9267 |
| 3004.90.9268 | 3004.90.9270 | 3004.90.9271 |
| 3004.90.9273 | 3004.90.9276 | |

For the purposes of this note:

(i) "Pharmaceutical articles" refers to imported articles classifiable in the provisions enumerated in this subdivision that are pharmaceutical products or that are ingredients (active pharmaceutical ingredients and key starting materials) classifiable in the provisions enumerated in this subdivision used to make pharmaceutical products.

(ii) "Patented pharmaceutical articles" are pharmaceutical articles that are subject to a valid, unexpired U.S. patent and are listed in the U.S. Food and Drug

Administration's ("FDA") Approved Drug Products with Therapeutic Equivalence Evaluations ("Orange Book") or in the FDA's Lists of Licensed Biological Products ("Purple Book"); and ingredients (active pharmaceutical ingredients and key starting materials) for such articles.

(iii) "Generic pharmaceutical articles" are FDA-approved pharmaceutical articles, and associated ingredients, that are not subject to a valid, unexpired U.S. patent and are off exclusivity. A generic pharmaceutical article is an active pharmaceutical ingredient or any component in a finished dosage form product that is used in a drug product or biosimilar biological product approved pursuant to a qualifying application; or a drug product or biosimilar biological product approved or licensed pursuant to a qualifying application. A qualifying application is: (a) an abbreviated new drug application submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act ("FDCA"); (b) a new drug application submitted under section 505(b)(2) of the FDCA that has been requested to be or that has been deemed therapeutically equivalent to a listed drug; (c) a biosimilar biologics application submitted under section 351(k) of the Public Health Services Act; or (d) an application for an authorized generic drug or authorized biological product, as those terms are described in section 505(t) of the FDCA and 42 U.S.C. § 1320f-1(e)(2)(B)(ii), provided that the products are imported by a generic or biosimilar manufacturer.

(d) Heading 9903.04.60 applies to patented pharmaceutical articles provided for in subdivision (c) of this note. For articles for which the applicable column 1 tariff rate is less than the additional duties provided by heading 9903.04.60, the sum of the column 1 duty rate and the additional *ad valorem* rate of duty shall be the rate of duty provided by heading 9903.04.60. For articles for which the applicable column 1 tariff rate is greater than the additional duties provided by heading 9903.04.60, then no additional duty is due pursuant to heading 9903.04.60.

(e) Heading 9903.04.61 applies to patented pharmaceutical articles imported for companies identified by the Secretary and imported before 12:01 am eastern time on September 29, 2026. The Secretary shall notify CBP of all such companies.

(f) Heading 9903.04.62 applies to patented pharmaceutical articles that are the product of Japan, of a member country of the European Union, of South Korea, of Switzerland, or of Liechtenstein that would otherwise be subject to the additional duties imposed under heading 9903.04.60. For articles for which the applicable column 1 tariff rate is less than the additional duties provided by heading 9903.04.62, the sum of the column 1 duty rate and the additional *ad valorem* rate of duty shall be the rate of duty provided by heading 9903.04.62. For articles for which the applicable column 1 tariff rate is greater than the additional duties provided by heading 9903.04.62, no additional duty is due pursuant to heading 9903.04.62.

(g) Heading 9903.04.63 applies to patented pharmaceutical articles that are the product of the United Kingdom that would otherwise be subject to the additional duties imposed under heading 9903.04.60.

(h) Headings 9903.04.64–9903.04.66 apply to patented pharmaceutical articles described in this subdivision. Any importer entering pharmaceutical articles under any of these headings shall provide any information that may be required, and in such form, as is deemed necessary by CBP to permit the administration of these headings.

(i) Heading 9903.04.64 applies to patented pharmaceutical articles imported for companies subject to an onshoring plan approved by the Secretary of Commerce in accordance with a process to be established in a Federal Register notice. The Secretary shall notify CBP of all such agreements.

(ii) Heading 9903.04.65 applies to patented pharmaceutical articles that meet the requirements of subdivision (h)(i) of this note and are imported for companies that have entered into a Most-Favored-Nation pharmaceutical pricing agreement with the Secretary of Health and Human Services. The Secretary of Commerce shall notify CBP of all such agreements.

(iii) Heading 9903.04.66 applies to drugs and associated ingredients for all approved indications that are designated as orphan pursuant to the Orphan Drug Act, 21 U.S.C. 360aa *et seq.* and its implementing regulations; nuclear medicines; plasma-derived therapies; fertility treatments; cell and gene therapies; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological and nuclear threats; or other specialty pharmaceutical products identified by the Secretary of Commerce or pharmaceutical products for animal health imported from a jurisdiction that has a current or forthcoming trade and security framework or that meet an urgent U.S. health need. The Secretary shall publish a Federal Register notice when the conditions above are met and shall notify CBP of all such products.

(i) Heading 9903.04.69 applies to entries of articles that are classifiable under provisions of the HTSUS enumerated in subdivision (c) of this note but that are not pharmaceutical articles described in subdivisions (c)(i)–(iii) of this note.

2. The following new headings are inserted in numerical sequence, with the material in each new heading inserted in the columns of the HTSUS labeled "Heading/Subheading", "Article Description", "Rates of Duty 1-General", "Rates of Duty 1-Special" and "Rates of Duty 2", respectively:

| Heading/ Subheading | Article Description | Rates of Duty | | |
|---|---|---|---|---|
| | | 1 | | 2 |
| | | General | Special | |
| "9903.04.60 | Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter..... | 100% | 100% | The duty provided in the applicable subheading |
| 9903.04.61 | Patented pharmaceutical articles entered before 12:01 a.m. eastern time on September 29, 2026 as provided for in subdivisions (c) and (e) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading | The duty provided in the applicable subheading | The duty provided in the applicable subheading |
| 9903.04.62 | Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter..... | 15% | 15% | The duty provided in the applicable subheading |
| 9903.04.63 | Patented pharmaceutical articles that are the product of the United Kingdom as defined in subdivisions (c) and (g) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading + 10% | The duty provided in the applicable subheading + 10% | The duty provided in the applicable subheading |
| 9903.04.64 | Patented pharmaceutical articles subject to a qualifying onshoring plan, as provided for in subdivisions (c) and (h)(i) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading + 20% | The duty provided in the applicable subheading + 20% | The duty provided in the applicable subheading |
| 9903.04.65 | Pharmaceutical articles subject to a qualifying onshoring plan and a Most-Favored-Nation pharmaceutical pricing agreement, as provided for in subdivisions (c) and (h)(ii) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading + 0% | The duty provided in the applicable subheading | The duty provided in the applicable subheading |

| | | | | |
|---|---|---|---|---|
| 9903.04.66 | Drugs and pharmaceutical articles for the specific uses provided in subdivisions (c) and (h)(iii) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading + 0% | The duty provided in the applicable subheading | The duty provided in the applicable subheading |
| 9903.04.67 | Generic pharmaceutical articles, as provided for in subdivision (c) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading | The duty provided in the applicable subheading | The duty provided in the applicable subheading |
| 9903.04.68 | Pharmaceutical products with an active pharmaceutical ingredient packaged in dosage form that is a product of the United States..... | The duty provided in the applicable subheading | The duty provided in the applicable subheading | The duty provided in the applicable subheading |
| 9903.04.69 | Articles as provided for in subdivision (i) of U.S. note 40 to this subchapter..... | The duty provided in the applicable subheading | The duty provided in the applicable subheading | The duty provided in the applicable subheading" |

3. U.S. note 2(aa)(v) is modified by:

   a. redesignating subdivisions (a)–(k) as (2)–(12); and

   b. inserting "(1) patented pharmaceutical articles provided for in headings 9903.04.60, 9903.04.61, 9903.04.62, 9903.04.63, 9903.04.64, 9903.04.65 and 9903.04. 66;" in numerical order.

4. Heading 9903.03.06 is modified by deleting ", or medium- and heavy-duty vehicles or medium- and heavy-duty vehicle parts," and inserting ", medium- and heavy-duty vehicles or medium- and heavy-duty vehicle parts, or patented pharmaceutical articles," in lieu thereof.

B. Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on January 20, 2029, subchapter III of chapter 99 of the HTSUS is modified as follows:

   a. subdivision (h)(ii) of U.S. note 40 to this subchapter is deleted;

   b. subdivision (h)(iii) of U.S. note 40 to this subchapter is renumbered as subdivision (h)(ii);

   c. heading 9903.04.65 is terminated and deleted; and

d. the article description of heading 9903.04.66 is modified by deleting "(h)(iii)" and inserting "(h)(ii)" in lieu thereof.

C. Effective with respect to goods entered for consumption, or withdrawn from warehouse for consumption, on or after 12:01 a.m. eastern time on April 2, 2030, heading 9903.04.64 is amended by deleting "20%" each place that it appears and inserting "100%" in lieu thereof.

**Annex II**

Below are the company-specific agreements related to Section 232 tariffs on pharmaceutical products and ingredients that the Secretary of Commerce entered into prior to this proclamation.

1. AbbVie Inc. dated March 20, 2026
2. Amgen Inc. dated December 19, 2025
3. AstraZeneca Pharmaceuticals, LP dated March 20, 2026
4. Bristol Myers Squibb dated December 19, 2025
5. Boehringer Ingelheim Pharmaceuticals, Inc. dated December 19, 2025
6. Eli Lilly and Company dated February 23, 2026
7. EMD Serono, Inc. dated February 12, 2026
8. Genentech, Inc. dated December 19, 2025
9. Gilead Sciences, Inc. dated December 19, 2025
10. Merck Sharp & Dohme LLC dated February 11, 2026
11. Novartis Pharmaceuticals Corporation dated February 12, 2026
12. Novo Nordisk Inc. dated February 23, 2026
13. Sanofi S.A. dated December 19, 2025

**Annex III**

Annex III of this proclamation lists the companies whose tariff treatment shall be effective 120 days from the date of this proclamation.

1. AbbVie Inc.
2. Amgen Inc.
3. AstraZeneca Pharmaceuticals, LP
4. Bristol Myers Squibb
5. Boehringer Ingelheim Pharmaceuticals, Inc.
6. Eli Lilly and Company
7. EMD Serono, Inc.
8. Genentech, Inc.
9. Gilead Sciences, Inc.
10. GlaxoSmithKline LLC and ViiV Healthcare Company
11. Johnson & Johnson
12. Merck Sharp & Dohme LLC
13. Novartis Pharmaceuticals Corporation
14. Novo Nordisk Inc.
15. Pfizer Inc.
16. Regeneron Pharmaceuticals, Inc.
17. Sanofi S.A.

**Annex IV**

This annex includes the list of HTSUS codes that are not covered under the Annex I actions of this proclamation and are subject to the Section 232 action related to pharmaceuticals and pharmaceutical ingredients with a tariff rate of zero. Pursuant to section (4) of Proclamation 11012 of February 20, 2026, "Imposing a Temporary Import Surcharge to Address Fundamental International Payments Problems," these codes are not subject to the surcharge imposed by Proclamation 11012.

| | | | | | |
|---|---|---|---|---|---|
| 2903.45.1000 | 2919.90.5010 | 2926.90.4801 | 2933.49.6000 | 2936.26.0000 | 3004.20.0076 |
| 2903.51.1000 | 2919.90.5050 | 2926.90.5010 | 2933.49.7000 | 2936.27.0000 | 3004.20.0080 |
| 2903.59.9000 | 2920.90.5100 | 2926.90.5050 | 2933.52.1000 | 2936.28.0000 | 3004.32.0010 |
| 2903.69.9000 | 2921.19.1100 | 2927.00.4000 | 2933.52.9000 | 2936.29.1000 | 3004.32.0040 |
| 2903.78.0000 | 2921.29.0010 | 2927.00.5000 | 2933.53.0000 | 2936.29.1610 | 3004.39.0020 |
| 2903.79.9030 | 2921.29.0020 | 2928.00.2500 | 2933.54.0000 | 2936.29.1620 | 3004.39.0030 |
| 2903.79.9070 | 2921.29.0030 | 2929.90.2000 | 2933.59.1000 | 2936.29.1630 | 3004.39.0040 |
| 2903.89.1500 | 2921.29.0055 | 2929.90.5015 | 2933.59.1500 | 2936.29.2000 | 3004.39.0045 |
| 2903.89.2000 | 2921.30.1000 | 2929.90.5018 | 2933.59.1800 | 2936.29.5020 | 3004.42.0000 |
| 2903.89.7010 | 2921.30.5000 | 2929.90.5020 | 2933.59.2200 | 2936.29.5030 | 3004.49.00 |
| 2903.89.7090 | 2921.42.9000 | 2929.90.5030 | 2933.59.7000 | 2936.29.5050 | 3004.50.1000 |
| 2903.92.0000 | 2921.46.0000 | 2929.90.5040 | 2933.59.8000 | 2936.90.0110 | 3004.50.2000 |
| 2904.99.4000 | 2921.49.4500 | 2929.90.5095 | 2933.59.8500 | 2936.90.0150 | 3004.50.3000 |
| 2905.29.9000 | 2921.49.5000 | 2930.20.2010 | 2933.59.9500 | 2937.21.0010 | 3004.50.4000 |
| 2905.39.9000 | 2921.59.8010 | 2930.20.2050 | 2933.69.6010 | 2937.21.0020 | 3004.50.5010 |
| 2905.59.1000 | 2921.59.8090 | 2930.20.9010 | 2933.69.6021 | 2937.21.0030 | 3004.50.5020 |
| 2905.59.9000 | 2922.11.0000 | 2930.20.9020 | 2933.69.6030 | 2937.21.0040 | 3004.50.5030 |
| 2906.19.5000 | 2922.14.0000 | 2930.20.9050 | 2933.69.6050 | 2937.23.1020 | 3004.50.5040 |
| 2906.29.6000 | 2922.19.2000 | 2930.30.6000 | 2933.72.0000 | 2937.23.2500 | 3004.60.0000 |
| 2907.29.9000 | 2922.19.3300 | 2930.90.2900 | 2933.79.1500 | 2937.23.50 | 3004.90.9203 |
| 2908.19.6000 | 2922.19.6000 | 2930.90.4910 | 2933.91.0010 | 2937.29.1000 | 3004.90.9204 |
| 2909.19.1800 | 2922.19.7000 | 2930.90.4920 | 2933.91.0050 | 2937.29.9020 | 3004.90.9205 |
| 2909.20.0000 | 2922.19.9000 | 2930.90.4950 | 2933.99.0100 | 2937.29.9030 | 3004.90.9207 |
| 2909.30.6000 | 2922.19.9610 | 2930.90.9208 | 2933.99.0200 | 2937.90.0500 | 3004.90.9209 |
| 2909.49.1000 | 2922.19.9619 | 2930.90.9210 | 2933.99.0500 | 2937.90.1000 | 3004.90.9212 |
| 2909.49.1500 | 2922.19.9690 | 2930.90.9212 | 2933.99.0600 | 2937.90.2000 | 3004.90.9213 |
| 2909.49.2000 | 2922.29.6100 | 2930.90.9222 | 2933.99.0800 | 2937.90.4000 | 3004.90.9217 |
| 2909.49.6000 | 2922.29.8110 | 2930.90.9225 | 2933.99.1100 | 2938.10.0000 | 3004.90.9218 |
| 2909.50.4010 | 2922.29.8190 | 2930.90.9231 | 2933.99.1200 | 2939.19.1000 | 3004.90.9219 |
| 2909.50.4050 | 2922.31.0000 | 2930.90.9251 | 2933.99.1600 | 2939.20.0010 | 3004.90.9220 |
| 2909.50.4500 | 2922.39.2500 | 2931.49.0005 | 2933.99.1701 | 2939.20.0050 | 3004.90.9222 |
| 2909.50.5000 | 2922.39.4500 | 2931.49.0008 | 2933.99.2200 | 2939.30.0000 | 3004.90.9223 |
| 2912.19.5000 | 2922.39.5000 | 2931.49.0010 | 2933.99.2400 | 2939.41.0000 | 3004.90.9224 |
| 2912.49.2600 | 2922.41.0010 | 2931.49.0015 | 2933.99.2600 | 2939.42.0000 | 3004.90.9226 |

| | | | | | |
|---|---|---|---|---|---|
| 2914.19.0000 | 2922.41.0090 | 2931.49.0020 | 2933.99.4200 | 2939.44.0000 | 3004.90.9227 |
| 2914.40.9000 | 2922.42.5000 | 2931.49.0025 | 2933.99.5100 | 2939.45.0000 | 3004.90.9228 |
| 2914.50.3000 | 2922.44.0000 | 2931.49.0055 | 2933.99.5510 | 2939.49.0300 | 3004.90.9229 |
| 2914.50.5000 | 2922.49.1000 | 2931.49.0080 | 2933.99.5520 | 2939.59.0000 | 3004.90.9230 |
| 2914.62.0000 | 2922.49.3000 | 2931.53.0000 | 2933.99.5530 | 2939.62.0000 | 3004.90.9232 |
| 2914.69.2100 | 2922.49.3700 | 2931.90.9010 | 2933.99.5800 | 2939.63.0000 | 3004.90.9233 |
| 2914.69.9000 | 2922.49.4910 | 2931.90.9021 | 2933.99.7900 | 2939.69.0000 | 3004.90.9234 |
| 2914.79.4000 | 2922.49.4915 | 2931.90.9025 | 2933.99.8210 | 2939.72.0000 | 3004.90.9235 |
| 2915.29.3000 | 2922.49.4950 | 2931.90.9029 | 2933.99.8220 | 2939.79.0000 | 3004.90.9237 |
| 2915.39.3100 | 2922.49.8000 | 2931.90.9030 | 2933.99.8290 | 2939.80.0010 | 3004.90.9238 |
| 2915.39.3500 | 2922.50.0700 | 2931.90.9035 | 2933.99.8500 | 2939.80.0050 | 3004.90.9239 |
| 2915.39.4700 | 2922.50.1000 | 2931.90.9040 | 2933.99.8900 | 2940.00.6000 | 3004.90.9240 |
| 2915.39.9000 | 2922.50.1100 | 2931.90.9052 | 2933.99.9701 | 2941.10.1000 | 3004.90.9241 |
| 2915.90.1010 | 2922.50.1300 | 2932.14.0000 | 2934.10.1000 | 2941.10.2000 | 3004.90.9242 |
| 2915.90.1050 | 2922.50.1700 | 2932.19.5100 | 2934.10.2000 | 2941.10.3000 | 3004.90.9244 |
| 2915.90.1400 | 2922.50.3500 | 2932.20.3000 | 2934.10.9000 | 2941.20.1000 | 3004.90.9245 |
| 2915.90.1810 | 2922.50.4000 | 2932.20.5010 | 2934.20.4000 | 2941.20.5000 | 3004.90.9247 |
| 2915.90.1890 | 2922.50.5000 | 2932.20.5020 | 2934.20.8000 | 2941.30.0000 | 3004.90.9248 |
| 2915.90.2000 | 2923.10.0000 | 2932.20.5030 | 2934.30.4300 | 2941.40.0000 | 3004.90.9250 |
| 2915.90.5010 | 2923.20.2010 | 2932.20.5050 | 2934.30.5000 | 2941.50.0000 | 3004.90.9254 |
| 2915.90.5050 | 2923.20.2050 | 2932.99.6100 | 2934.91.0000 | 2941.90.1010 | 3004.90.9255 |
| 2916.19.3000 | 2924.11.0000 | 2932.99.7000 | 2934.92.0000 | 2942.00.3500 | 3004.90.9256 |
| 2916.19.5000 | 2924.19.1110 | 2932.99.9010 | 2934.99.0100 | 2942.00.5000 | 3004.90.9257 |
| 2916.20.5000 | 2924.19.1120 | 2932.99.9090 | 2934.99.0300 | 3001.20.0000 | 3004.90.9258 |
| 2916.31.5000 | 2924.19.1130 | 2933.11.0000 | 2934.99.0500 | 3001.90.0110 | 3004.90.9261 |
| 2916.39.4600 | 2924.19.1150 | 2933.19.9000 | 2934.99.0600 | 3001.90.0150 | 3004.90.9262 |
| 2916.39.7900 | 2924.19.8000 | 2933.21.0000 | 2934.99.0700 | 3001.90.0165 | 3004.90.9264 |
| 2917.13.0030 | 2924.21.1600 | 2933.29.0500 | 2934.99.0800 | 3001.90.0195 | 3004.90.9265 |
| 2917.13.0090 | 2924.21.5000 | 2933.29.3500 | 2934.99.0900 | 3002.12.0010 | 3004.90.9266 |
| 2917.19.1000 | 2924.29.0100 | 2933.29.4300 | 2934.99.1100 | 3002.12.0020 | 3004.90.9269 |
| 2917.19.7020 | 2924.29.0300 | 2933.29.6000 | 2934.99.1200 | 3002.12.0030 | 3004.90.9272 |
| 2917.19.7050 | 2924.29.1000 | 2933.29.9000 | 2934.99.1500 | 3002.12.0090 | 3004.90.9274 |
| 2917.34.0110 | 2924.29.2300 | 2933.33.0100 | 2934.99.1600 | 3002.13.00 | 3004.90.9275 |
| 2917.34.0150 | 2924.29.2600 | 2933.34.0000 | 2934.99.1800 | 3002.14.00 | 3006.30.1000 |
| 2917.39.3000 | 2924.29.2800 | 2933.35.0000 | 2934.99.2000 | 3002.15.00 | 3006.30.5000 |
| 2918.11.5100 | 2924.29.3300 | 2933.37.0000 | 2934.99.3900 | 3002.49.0010 | 3006.60.0000 |
| 2918.13.5000 | 2924.29.5700 | 2933.39.0800 | 2934.99.4400 | 3002.90.5210 | 3006.70.0000 |
| 2918.16.5010 | 2924.29.6210 | 2933.39.1000 | 2934.99.7000 | 3003.10.0000 | 3006.93.1000 |
| 2918.16.5020 | 2924.29.6220 | 2933.39.2000 | 2934.99.9001 | 3003.41.0000 | 3006.93.2000 |
| 2918.16.5090 | 2924.29.7100 | 2933.39.2100 | 2935.50.0000 | 3003.42.0000 | 3006.93.5000 |
| 2918.19.6000 | 2924.29.7710 | 2933.39.2300 | 2935.90.0600 | 3003.90.0160 | 3006.93.6000 |

| | | | | | |
|---|---|---|---|---|---|
| 2918.19.9000 | 2924.29.7720 | 2933.39.2500 | 2935.90.1000 | 3004.10.1020 | 3006.93.8000 |
| 2918.22.1000 | 2924.29.7730 | 2933.39.2700 | 2935.90.1300 | 3004.10.1045 | |
| 2918.22.5000 | 2924.29.7790 | 2933.39.3100 | 2935.90.1500 | 3004.10.5048 | |
| 2918.23.3000 | 2924.29.8000 | 2933.39.6110 | 2935.90.2000 | 3004.10.5049 | |
| 2918.23.5000 | 2924.29.9500 | 2933.39.6120 | 2935.90.3000 | 3004.10.5055 | |
| 2918.29.2000 | 2925.12.0000 | 2933.39.6130 | 2935.90.3200 | 3004.10.5065 | |
| 2918.29.6500 | 2925.19.4200 | 2933.39.6191 | 2935.90.3300 | 3004.10.5075 | |
| 2918.29.7500 | 2925.19.9100 | 2933.39.9200 | 2935.90.4200 | 3004.20.0020 | |
| 2918.30.2500 | 2925.21.0000 | 2933.41.0000 | 2935.90.7500 | 3004.20.0030 | |
| 2918.30.3000 | 2925.29.6000 | 2933.49.0800 | 2935.90.9500 | 3004.20.0045 | |
| 2918.30.9000 | 2925.29.9000 | 2933.49.1000 | 2936.21.0000 | 3004.20.0055 | |
| 2918.99.4300 | 2926.30.1000 | 2933.49.1500 | 2936.22.0000 | 3004.20.0065 | |
| 2918.99.4700 | 2926.40.0000 | 2933.49.1700 | 2936.23.0000 | 3004.20.0070 | |
| 2918.99.5000 | 2926.90.1400 | 2933.49.2000 | 2936.24.0100 | 3004.20.0071 | |
| 2919.90.3000 | 2926.90.4300 | 2933.49.3000 | 2936.25.0000 | 3004.20.0072 | |

○